Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?

Inka Miñambres, Antonio Pérez

Research output: Contribution to journalReview articleResearchpeer-review

15 Citations (Scopus)


© 2017 The Author(s). Several GLP-1 receptor agonists are currently available for treatment of type 2 diabetic patients. Based on their pharmacokinetic/pharmacodynamic profile, these drugs are classified as short-acting GLP-1 receptor agonists (exenatide and lixisenatide) or long-acting GLP-1 receptor agonists (exenatide-LAR, liraglutide, albiglutide, and dulaglutide). In clinical practice, they are also classified as basal or prandial GLP-1 receptor agonists to differentiate between patients who would benefit more from one or another based on characteristics such as previous treatment and the predominance of fasting or postprandial hyperglycemia. In the present article we examine available data on the pharmacokinetic characteristics of the various GLP-1 agonists and compare their effects with respect to the main parameters used to evaluate glycemic control. The article also analyzes whether the differences between the different GLP-1 agonists justify their classification as basal or prandial.
Original languageEnglish
Article number6
JournalDiabetology and Metabolic Syndrome
Issue number1
Publication statusPublished - 18 Jan 2017


  • GLP-1 receptor agonists
  • Glycemic control
  • Postprandial glycemia
  • Type 2 diabetes mellitus


Dive into the research topics of 'Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?'. Together they form a unique fingerprint.

Cite this